
EU Regulators Back Moving Teclistamab Earlier in Multiple Myeloma Treatment: What the MajesTEC-9 Data Actually Show
10 min readA CHMP opinion — not an approval — backs teclistamab monotherapy after one prior line, on Phase 3 data showing a 71% reduction in progression or death alongside higher high-grade toxicity.










